Most Read Articles
Roshini Claire Anthony, 6 days ago

For coffee drinkers, drinking filtered coffee may be tied to a lower mortality risk, including cardiovascular disease (CVD)-related mortality, a study from Norway suggested.

4 days ago
Use of corticosteroid is not associated with improved outcomes in idiopathic pulmonary fibrosis (IPF) patients admitted to the hospital with acute exacerbation (AE), reveals a recent study. In addition, corticosteroids may even contribute to reduced overall survival following exacerbation.
Dr. Wong Soon Tee, 28 May 2020
Acne is a common skin problem seen in primary care. Dr Wong Soon Tee of Assurance Skin Clinic at Mt Elizabeth Novena Hospital, Singapore shares his insights with Pearl Toh on how to manage acne in the primary care setting.
27 May 2020
The perception that proton pump inhibitors (PPIs) cause multiple serious adverse effects (AEs) is supported by many internists, who then recommend treatment cessation even in patients at high risk for upper gastrointestinal bleeding (UGIB), reveals a study.

Fixed-dose ibuprofen–acetaminophen combo a viable nonopioid option for acute pain

04 May 2020

Fixed-dose combination of ibuprofen (IBU) and acetaminophen (APAP) produces better analgesic effects compared with either drug alone, as the combination acts rapidly, relieves pain for >8 hours, and is well tolerated, a study has shown.

Researchers examined data from two phase III dental pain studies involving healthy young patients who had moderate-to-severe pain after ≥3 molar extractions. The patients had received a single-dose fixed-dose combination of IBU/APAP 250 mg/500 mg (FDC), IBU 250 mg, APAP 650 mg, or placebo. Effects were evaluated over 12 hours (trial 1) or over 48 hours (trial 2).

A total of 568 patients were included in trial 1 and 123 in trial 2. The primary outcomes were time-weighted sum of pain intensity differences over 8 (SPID[11]0–8) and 24 (SPID[11]0–24) hours, respectively. Other assessments were time to meaningful pain relief (TMPR), duration of pain relief and tolerability.

In trial 1, results for SPID[11]0–8 significantly favoured FDC over placebo, IBU and APAP (p<0.001, p=0.008 and p<0.001, respectively). The same was true in trial 2, where FDC produced greater improvements in SPID[11]0–24 compared with placebo (p<0.001), in addition to having sustained efficacy during multiple dosing.

FDC demonstrated a rapid onset of action, with TMPR occurring within 1 hour of administration. Pain relief duration was >8 hours in both trials.

In terms of safety, FDC was well tolerated. The rates of adverse events were lowest with the combination.

Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 6 days ago

For coffee drinkers, drinking filtered coffee may be tied to a lower mortality risk, including cardiovascular disease (CVD)-related mortality, a study from Norway suggested.

4 days ago
Use of corticosteroid is not associated with improved outcomes in idiopathic pulmonary fibrosis (IPF) patients admitted to the hospital with acute exacerbation (AE), reveals a recent study. In addition, corticosteroids may even contribute to reduced overall survival following exacerbation.
Dr. Wong Soon Tee, 28 May 2020
Acne is a common skin problem seen in primary care. Dr Wong Soon Tee of Assurance Skin Clinic at Mt Elizabeth Novena Hospital, Singapore shares his insights with Pearl Toh on how to manage acne in the primary care setting.
27 May 2020
The perception that proton pump inhibitors (PPIs) cause multiple serious adverse effects (AEs) is supported by many internists, who then recommend treatment cessation even in patients at high risk for upper gastrointestinal bleeding (UGIB), reveals a study.